DZD Announces Positive Data from Multiple Studies Demonstrating Promise of New Technology
October 21 2020
Initial results show new class of diagnostics can provide culture-free pathogen identification and drug-resistance profile within hours, not days
Read More
DZD Research Highlighted in Two Publications on Plasmid-Mediated Antibiotic Resistance
June 2 2020
DZD technical expertise enables identification of novel mechanisms of antibiotic resistance using nanopore sequencing
Read More
DZD Awarded $6.2M Non-Dilutive Funding to Develop Rapid Antibiotic Resistance Diagnostic
May 11 2020
CARB-X selects Day Zero Diagnostics for their global portfolio of technologies to combat antibiotic-resistance
Read More
EpiXact® Helps Stop a Carbapenem-Resistant Acinetobacter baumannii Outbreak in a Burn ICU
February 28 2020
Research published in Infection Control and Hospital Epidemiology details use of patient and environmental whole genome sequencing to stop a CRAB outbreak
Read More
EpiXact® Used to Identify Drug-Resistant E. coli Transmitted by Fecal Microbiota Transplant
November 6 2019
EpiXact confirms cause of first patient death reported from an FMT procedure in research published in the New England Journal of Medicine
Read More
DZD Presents at Presidential Advisory Council on Combating Antibiotic Resistant Bacteria
July 10 2019
CEO Jong Lee delivers DZD technology overview to Council
Read More